Opaleye sells 126,685 Eton Pharma shares
Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, Inc., reported open-market sales totaling 126,685 shares of common stock from July 2 to July 7, 2026.
Rhea-AI Filing Summary
Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, Inc., reported open-market sales totaling 126,685 shares of common stock from July 2 to July 7, 2026. The trades were executed at weighted average prices around $37–$38 per share.
Shares were sold through Opaleye, L.P. and a separately managed account for which Opaleye Management serves as investment manager or portfolio manager. After these transactions, Opaleye, L.P. held 2,680,000 shares, and the managed account held 53,315 shares. Opaleye Management states it may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 126,685 shares
Net Sell
5 txns
Insider
Opaleye Management Inc.
Role
10% Owner
Sold
126,685 shs ($4.77M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock, par value $0.001 per share | 20,000 | $38.3728 | $767K |
| Sale | Common Stock, par value $0.001 per share | 6,685 | $38.3728 | $257K |
| Sale | Common Stock, par value $0.001 per share | 10,000 | $38.00 | $380K |
| Sale | Common Stock, par value $0.001 per share | 65,000 | $37.3851 | $2.43M |
| Sale | Common Stock, par value $0.001 per share | 25,000 | $37.3851 | $935K |
Holdings After Transaction:
Common Stock, par value $0.001 per share — 2,680,000 shares (Indirect, By Opaleye, L.P.);
Common Stock, par value $0.001 per share — 53,315 shares (Indirect, By Managed Account)
Footnotes (5)
- F1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
- F2. Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Managed Account.
- F3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.05 to $37.85 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
- F4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.565 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
- F5. Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Key Figures
Total shares sold: 126,685 shares
Sale price (higher tranche): $38.3728 per share
Sale price (lower tranche): $37.3851 per share
+2 more
5 metrics
Total shares sold
126,685 shares
Aggregate open-market sales July 2–7, 2026
Sale price (higher tranche)
<money>$38.3728</money> per share
Open-market sales on July 6–7, 2026
Sale price (lower tranche)
<money>$37.3851</money> per share
Open-market sales on July 2, 2026
Opaleye, L.P. holdings
2,680,000 shares
Common stock held after July 7, 2026 sales
Managed account holdings
53,315 shares
Common stock held after July 7, 2026 sales
Key Terms
open-market sale, weighted average price, separately managed account, beneficial ownership, +1 more
5 terms
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
separately managed account financial
"Securities owned by a separately managed account (the "Managed Account")."
A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.
beneficial ownership financial
"may be deemed to beneficially own the securities owned directly by the Fund."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein"
FAQ
What insider activity did Opaleye Management report for ETON in this Form 4?
Opaleye Management reported open-market sales totaling 126,685 Eton Pharmaceuticals shares. The trades occurred between July 2 and July 7, 2026, at weighted average prices around $37–$38 per share through a fund and a separately managed account.
At what prices were the recent Eton Pharmaceuticals (ETON) insider sales executed?
The reported Eton Pharmaceuticals shares were sold at weighted average prices near $37.39 and $38.37. Footnotes state individual trades ranged from $37.05 to $37.85 and from $38.00 to $38.565, reflecting multiple transactions within each price band.
What are the Eton Pharmaceuticals holdings in the separately managed account?
A separately managed account associated with Opaleye Management sold 25,000 and 6,685 Eton Pharmaceuticals shares. After these open-market sales, the account’s reported position was 60,000 shares on July 2, 2026 and 53,315 shares on July 7, 2026, based on post-transaction balances.
Were the Eton Pharmaceuticals (ETON) insider trades part of a derivative exercise?
No, all reported transactions involve non-derivative common stock sales. The Form 4 lists open-market sale code “S” for each trade and shows no derivative securities or option exercises, with the derivative transaction summary fields remaining empty in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
